The Life Raft Group is committed to enhancing the survival and quality of life for people living with Gastrointestinal Stromal Tumor (GIST), and other rare diseases, through patient-powered research, education and empowerment, and global advocacy efforts.
Other Programs Supported by The Life Raft Group:
PATIENT
Leverage patient perspective to drive innovative solutions in cancer research.
POWERED
Educate and empower patients to take a larger role in their care.
SCIENCE
Accelerate research outcomes through collaborative efforts.
FOR LIFE
Increase access to effective treatments worldwide.
Real World Evidence In Action
Traditional models for cancer research have resulted in many breakthrough treatments for patients, but it is not enough. The LRG’s approach to GIST research through real world evidence, relies on timely, accurate data from the patient’s perspective, with patient survival as the primary objective.
RECENT LRG DATA
Did you know that GIST is actually a family of cancers? Learn more about the science of GIST.
Update your Patient Registry Info.
Join The Life Raft Group.
Current GIST Clinical Trials.
Search the GIST Specialist Database.
Dr. Monica Anderson
Diagnosed in 2012 with Adult GIST.
Bella Rocco
Diagnosed in 2009 with Pediatric
(SDH-deficient) GIST.
HELP US SAVE LIVES
The Life Raft Group is a community and it is up to all of us to make a difference. There are many ways to help. We always need patient tissue and data in our GIST patient registry. Volunteering your time or making a monetary donation also helps us drive research forward and save lives.
News
LRG Urges Governor Christie to Restore Cancer Funding
The LRG is continually involved in advocacy efforts to increase government spending on cancer research. We have joined forces with other cancer agencies to once again urge Governor Chris Christie and the New Jersey Legislature to restore the $1 million budget appropriation
Ovarian Cancer Treatment Flaws Revealed In New Study
Ovarian cancer treatment flaws have been exposed during a recent study, according to an article in the New York Times. The study was conducted by Dr. Robert E. Bristow, director of gynecologic oncology at the University of California, Irvine.
The LRG Celebrates Rare Disease Day
Today is Rare Disease day, and since GIST is a rare disease we felt it important to remind everyone to take action. The Life Raft Group works hard to advocate for & support our members and their loved ones, but we need your help.
FDA approves Stivarga for advanced GIST
The Food and Drug Administration, in a much-anticipated announcement for Gastrointestinal Stromal Tumor patients, has approved Bayer Pharmaceutical's drug, Stivarga, for use as a third-line treatment for advanced GIST.
The LRG Pushes for New Ways to Research Rare Disease
Communication is a two-way street, but unfortunately that is not always the case when finding ways to research rare disease. Sharing of [...]
NIH Announces Pediatric and Wildtype GIST Clinic for June
A GIST Clinic has been announced by the National Institutes of Health. The upcoming "Pediatric and wildtype GIST Clinic" at the [...]
Naturopathic Physician Dr. Alex Reimann Devotes Life to Cancer Patients and others In Need
Dr. Alex Reimann is a leading naturopathic physician. She has devoted her life to cancer patients and others in need.
Antibody Slows GIST Growth According to Stanford University Study
A recent study at Stanford University School of Medicine shows that an antibody slows GIST growth. The study shows that the antibody binds itself to the surface of a GIST Tumor and causes the growth of cancer cells to slow in the mice they tested.
Keep up with the latest news, events, and opportunities to help.
To contact The Life Raft Group, please call 973-837-9092
PARTNERS & AFFILIATIONS
